 In-PharmaTechnologist.com | Lonza Reaffirms Commitment to Teva Biosimilars JV in Light of 'Inaccurate ... In-PharmaTechnologist.com News of the strategy review follows a few months after Teva halted a Phase III trial of TL011 , a biosimilar version of Swiss drugmaker Roche's Rituxan/MabThera (rituximab). According to a report in Israeli newspaper Haaretz at the time development was ... |
